在本临床研究中,研究人员测试了溶瘤腺病毒Delta24-RGD在复发胶质母细胞瘤患者中的应用。这种腺病毒的独特之处在于,其无法在正常细胞中复制,但可以在Rb通路失活的细胞中复制。而此信号通路在超过90%的胶质瘤中失活,这使得溶瘤腺病毒Delta24...
Adenovirus Delta-24-RGD has shown a remarkable efficacy in a phase I clinical trial for glioblastoma. Delta-24-RGD induces autophagy in glioma cells, however, the molecular derangements associated with Delta-24-RGD infection remains poorly understood. Here, proteomics was applied to characterize the...
Delta-24-RGD is a replication competent adenovirus engineered to replicate in tumor cells with an aberrant RB pathway. This virus has proven to be safe and effective in adult gliomas. Here we report that the administration of Delta-24-RGD is safe in mice and results in a significant increase...
Human adenovirus 5 (Ad5)-based oncolytic recombinant viruses (rAds) have been the most commonly used across many cancer types in clinical trials. Ad5-delta-24-RGD (DNX-2401) is a replication-competent, infectivity-enhanced rAd1, which is currently under investigation in a number of phase I/...
Delta-24-RGD induced immune cells infiltration in GL261 mouse glioma xenografts.Hong JiangKaren CliseDwyerKathryn E. RuisaardXuejun FanWeihua TianJoy GuminMartine L. LamfersAnne KleijnFrederick F. LangWaiKwan Alfred Yung
Examination of the Therapeutic Potential of Delta-24-RGD in Brain Tumor Stem Cells: Role of Autophagic Cell Death Hong Jiang, Candelaria Gomez-Manzano, Hiroshi Aoki, Marta M. Alonso, Seiji Kondo, Frank McCormick, Jing Xu, Yasuko Kondo, B. Nebiyou Bekele, Howard Colman, Frederick F. Lang,...
As part of a phase 1, dose-escalation, biological-endpoint clinical study (NCT00805376) of DNX-2401 (Delta-24-RGD), a Rb-targeted, tumor-selective, replication-competent oncolytic adenovirus, conducted in 37 patients with recurrent malignant glioma, 12 patients received an intratumoral injection th...
Examination of the therapeutic potential of Delta-24-RGD in brain tumor stem cells： role of aut 维普资讯 http://www.cqvip.com
Delta-24-RGD (DNX-2401 in the clinic), is a tumor specific oncolytic adenovirus that has been tested in preclinical and clinical studies in adult high grade glioma, demonstrating its safe profile and certain degree of efficacy. The objective of this work was to evaluate the safety and the ...
Here we investigate the effect of Delta-24-RGD oncolytic adenovirus on innate and adaptive anti-glioma immunity. Design: Mouse GL261-glioma model was set up in immunocompetent C57BL/6 mouse for Delta-24-RGD treatment. The changes of the immune cell populations were analyzed by ...